<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580472</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-19-482</org_study_id>
    <nct_id>NCT04580472</nct_id>
  </id_info>
  <brief_title>Utility of Single-dose Oral Antibiotic Prophylaxis in Prevention of Surgical Site Infection in Dermatologic Surgery</brief_title>
  <official_title>Utility of Single-dose Oral Antibiotic Prophylaxis in Prevention of Surgical Site Infection in Dermatologic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carilion Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carilion Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the effectiveness of a single dose of preoperative&#xD;
      antibiotic in reducing surgical site infections in certain dermatological procedures.&#xD;
      Patients will undergo surgical excision or Mohs surgery as is clinically indicated and part&#xD;
      of usual care. The study will be a double blinded, placebo-controlled clinical trial.&#xD;
      Patients meeting inclusion criteria will be assigned to one of three participant categories:&#xD;
      1) patients undergoing repair with skin flap or graft on the nose, 2) patients undergoing&#xD;
      repair with skin graft, flap, or wedge resection on the ear, or 3) patients undergoing Mohs&#xD;
      surgery with closure or partial closure or surgical excision on the lower extremity below the&#xD;
      knee. Within each category, participants will be randomized into one of two groups: group one&#xD;
      will receive a preoperative placebo pill and group two will receive preoperative antibiotic&#xD;
      prophylaxis (either a single dose of Cephalexin 2g PO or single dose of Clindamycin&#xD;
      hydrochloride 600 mg PO if allergy to penicillin or cephalosporin).&#xD;
&#xD;
      Patients will followed for 30 days +/- 7 after surgery to evaluate for any surgical site&#xD;
      infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients meeting inclusion criteria will be assigned to one of three participant categories: 1) patients undergoing repair with skin flap or graft on the nose, 2) patients undergoing repair with skin graft, flap, or wedge resection on the ear, or 3) patients undergoing Mohs surgery with closure or partial closure or surgical excision on the lower extremity below the knee. Within each category, participants will be randomized into one of two groups: group one will receive a preoperative placebo pill and group two will receive preoperative antibiotic prophylaxis (either a single dose of Cephalexin 2g PO or single dose of Clindamycin hydrochloride 600 mg PO if allergy to penicillin or cephalosporin). These doses for cephalexin and clindamycin hydrochloride are standard doses for adults. The administration time of the oral antibiotics (as well for placebo group) will be 5-15 minutes prior to surgery in the nose and ear group and 30 minutes prior incision in the leg group.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants will not be told if they are receiving the antibiotic or placebo. Dermatologic surgeons who are performing the surgery and assessing for surgical site infections will be blinded to which arm of the study the patient is randomized. In order to accomplish this, study nurses will be responsible for randomizing each participant and will administer the antibiotic or placebo to each participant after each patient has consented and after the dermatologic surgeon has placed the order for &quot;cephalexin/placebo&quot; or &quot;clindamycin/placebo&quot; (based on patient's allergies) in the electronic medical record.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Development of surgical site infection within 30 days of surgery</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of surgical site infection occurrence</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Surgical Site Infection</condition>
  <arm_group>
    <arm_group_label>Placebo - leg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>If randomized to placebo group, 4 placebo capsules will be administered PO 30 minutes prior to incision in the leg group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic- leg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The administration time of the oral antibiotics will be 30 minutes prior to incision in the leg group. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo- nose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>If randomized to placebo group, 4 placebo capsules will be administered PO 5-15 minutes prior to surgery on the nose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic- nose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The administration time of the oral antibiotics will be 5-15 minutes prior to surgery on the nose. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered PO.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo- ear</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>If randomized to placebo group, 4 placebo capsules will be administered PO 5-15 minutes prior to surgery on the ear.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic- ear</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The administration time of the oral antibiotics will be 5-15 minutes prior to surgery on the ear. 4-500 mg capsules of cephalexin will be administered to the patient. If there is concern for previous allergy to cephalexin, 4-150 mg capsules of clindamycin hydrochloride will be administered PO.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cephalexin</intervention_name>
    <description>If randomized to the antibiotic group, a single dose of cephalexin or clindamycin hydrochloride (if concern for previous allergy to Cephalexin) will be given prior to surgery.</description>
    <arm_group_label>Antibiotic- ear</arm_group_label>
    <arm_group_label>Antibiotic- leg</arm_group_label>
    <arm_group_label>Antibiotic- nose</arm_group_label>
    <other_name>Clindamycin hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <description>Patients will receive 4 placebo capsules prior to surgery if randomized to placebo group.</description>
    <arm_group_label>Placebo - leg</arm_group_label>
    <arm_group_label>Placebo- ear</arm_group_label>
    <arm_group_label>Placebo- nose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  presenting to Carilion Clinic Dermatology and Mohs surgery in Roanoke, VA at Riverside&#xD;
             1&#xD;
&#xD;
          -  suspected to undergo a single-staged repair including a skin flap or graft on the nose&#xD;
&#xD;
          -  OR suspected to undergo single-staged repair including a skin graft or flap or wedge&#xD;
             resection 1 on the ear&#xD;
&#xD;
          -  OR undergoing Mohs with closure or partial closure or surgical excision on the lower&#xD;
             extremity below the knee&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with intellectual or mental impairment affecting ability to give informed&#xD;
             consent&#xD;
&#xD;
          -  use of any antibiotic (other than intervention) within 48 hours of the surgery&#xD;
             suspected infection at time of surgery&#xD;
&#xD;
          -  inability to take cephalexin or clindamycin hydrochloride due to allergy or&#xD;
             intolerance current inflammatory skin disease affecting the surgical site&#xD;
&#xD;
          -  Patients undergoing concurrent surgery to oral or nasal mucosa&#xD;
&#xD;
          -  Patients who have had a recent prosthetic joint surgery within two years and have been&#xD;
             told they require antibiotic prophylaxis.&#xD;
&#xD;
          -  Patients who are currently pregnant, concerned they could be pregnant, actively trying&#xD;
             to conceive, or missed last menstrual period that is not explainable by a birth&#xD;
             control method.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariana Phillips, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carilion Clinic Dermatology and Mohs Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariana Phillips, MD</last_name>
    <phone>540-224-5170</phone>
    <email>maphillips@carilionclinic.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane Gay, BA</last_name>
    <email>jagay01@vt.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Carilion Clinic</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Phillips</last_name>
      <phone>540-224-5170</phone>
      <email>maphillips@carilionclinic.org</email>
    </contact>
    <contact_backup>
      <last_name>Jane Gay</last_name>
      <phone>5403368811</phone>
      <email>jagay01@vt.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Carilion Clinic</investigator_affiliation>
    <investigator_full_name>Mariana Phillips</investigator_full_name>
    <investigator_title>Section Chief of Dermatology &amp; Mohs Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Cephalexin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 31, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT04580472/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

